Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

BRCA1 promoter methylation predicts adverse ovarian cancer prognosis.

Chiang JW, Karlan BY, Cass L, Baldwin RL.

Gynecol Oncol. 2006 Jun;101(3):403-10. Epub 2005 Dec 19.

PMID:
16360812
2.

Methylation not a frequent "second hit" in tumors with germline BRCA mutations.

Dworkin AM, Spearman AD, Tseng SY, Sweet K, Toland AE.

Fam Cancer. 2009;8(4):339-46. doi: 10.1007/s10689-009-9240-1. Epub 2009 Apr 2.

PMID:
19340607
3.

BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.

Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S, Karlan BY.

Cancer Res. 2000 Oct 1;60(19):5329-33.

4.

"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.

Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, Ardern-Jones A, Norman A, Kaye SB, Gore ME.

J Clin Oncol. 2008 Dec 1;26(34):5530-6. doi: 10.1200/JCO.2008.16.1703. Epub 2008 Oct 27.

PMID:
18955455
5.

Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.

Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE.

Breast Cancer Res. 2006;8(4):R38.

6.

Failure of BRCA1 dysfunction to alter ovarian cancer survival.

Buller RE, Shahin MS, Geisler JP, Zogg M, De Young BR, Davis CS.

Clin Cancer Res. 2002 May;8(5):1196-202.

7.

Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer.

Bianco T, Chenevix-Trench G, Walsh DC, Cooper JE, Dobrovic A.

Carcinogenesis. 2000 Feb;21(2):147-51.

PMID:
10657950
8.

Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.

Lose F, Duffy DL, Kay GF, Kedda MA, Spurdle AB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer; Australian Ovarian Cancer Study Management Group.

J Natl Cancer Inst. 2008 Nov 5;100(21):1519-29. doi: 10.1093/jnci/djn345. Epub 2008 Oct 28.

PMID:
18957670
9.

BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?

Cass I, Holschneider C, Datta N, Barbuto D, Walts AE, Karlan BY.

Obstet Gynecol. 2005 Dec;106(6):1327-34.

PMID:
16319259
10.

High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors.

Wilcox CB, Baysal BE, Gallion HH, Strange MA, DeLoia JA.

Cancer Genet Cytogenet. 2005 Jun;159(2):114-22.

PMID:
15899382
11.

Improved survival in women with BRCA-associated ovarian carcinoma.

Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY.

Cancer. 2003 May 1;97(9):2187-95.

12.

Frequency of BRCA1 dysfunction in ovarian cancer.

Geisler JP, Hatterman-Zogg MA, Rathe JA, Buller RE.

J Natl Cancer Inst. 2002 Jan 2;94(1):61-7.

PMID:
11773283
13.

Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1.

Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, LiVolsi VA, Berchuck A, Muto MG, Garber JE, Weber BL, Lynch HT, Boyd J.

N Engl J Med. 1996 Nov 7;335(19):1413-6.

14.

Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.

Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S.

J Clin Oncol. 2008 Jan 1;26(1):20-5. doi: 10.1200/JCO.2007.11.6905.

PMID:
18165636
15.

Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1.

Aida H, Takakuwa K, Nagata H, Tsuneki I, Takano M, Tsuji S, Takahashi T, Sonoda T, Hatae M, Takahashi K, Hasegawa K, Mizunuma H, Toyoda N, Kamata H, Torii Y, Saito N, Tanaka K, Yakushiji M, Araki T, Tanaka K.

Clin Cancer Res. 1998 Jan;4(1):235-40.

16.
17.

Analyses of p53 expression pattern and BRCA mutations in patients with double primary breast and ovarian cancer.

Bruchim I, Fishman A, Friedman E, Goldberg I, Chetrit A, Barshack I, Dekel E, Hirsh-Yechezkel G, Modan B, Kopolovic J.

Int J Gynecol Cancer. 2004 Mar-Apr;14(2):251-8.

PMID:
15086724
18.

High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland.

Brozek I, Ochman K, Debniak J, Morzuch L, Ratajska M, Stepnowska M, Stukan M, Emerich J, Limon J.

Gynecol Oncol. 2008 Feb;108(2):433-7. Epub 2007 Nov 7.

PMID:
17997147
19.

Survival of BRCA1 negative ovarian cancer patients based on family history.

Chu CS, Morgan MA, Randall TC, Bandera CA, Rubin SC.

Gynecol Oncol. 2001 Oct;83(1):109-14.

PMID:
11585421
20.

BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.

Dann RB, DeLoia JA, Timms KM, Zorn KK, Potter J, Flake DD 2nd, Lanchbury JS, Krivak TC.

Gynecol Oncol. 2012 Jun;125(3):677-82. doi: 10.1016/j.ygyno.2012.03.006. Epub 2012 Mar 8.

PMID:
22406760

Supplemental Content

Support Center